Outset Medical Resumes Shipment of Tablo Systems for Home Use, Reports Second Quarter 2022 Financial Results and Provides 2022 Guidance

Rhea-AI Summary

Outset Medical, Inc. (Nasdaq: OM) announces FDA clearance for the Tablo® Hemodialysis System and resumes shipments for home use, reflecting a commitment to patient autonomy in dialysis.

For Q2 2022, revenue reached $25.1 million, matching prior guidance, with gross margin improving to 15.1% compared to 4.2% in Q2 2021. However, operating expenses rose to $47.5 million, contributing to a net loss of ($43.8) million.

Full-year guidance projects revenue between $105 million and $110 million, indicating modest growth over 2021.

Positive

• FDA clearance for Tablo® Hemodialysis System for home use.
• Revenue of $25.1 million in Q2 2022 aligns with prior guidance.
• Improved gross margin to 15.1%, up from 4.2% year-over-year.
• Service revenue increased by 18.5% compared to Q2 2021.
• Projected revenue growth of 2% to 7% for full year 2022.

Negative

• Net loss increased to ($43.8) million in Q2 2022 from ($30.2) million in Q2 2021.
• Operating expenses rose to $47.5 million, up from $31.0 million year-over-year.
• Product revenue decreased by 4.9% compared to Q2 2021.

Investor Webcast and Conference Call Scheduled for 5:00 p.m. EST

SAN JOSE, Calif.--(BUSINESS WIRE)-- Outset Medical, Inc. (Nasdaq: OM) (“Outset” or the “Company”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced clearance by the Food and Drug Administration of its previously disclosed 510(k) submission and resumption of Tablo^® Hemodialysis System shipments for home use.

The Company also reported financial results for the second quarter ended June 30, 2022 and provided financial guidance for 2022. Revenue for the second quarter totaled $25.1 million, in line with guidance provided on June 13, 2022. Gross margin for the second quarter was 15.1%, compared to 4.2% in the second quarter of 2021 and 14.5% in the first quarter of 2022.

“We are pleased to begin supporting new patients in the home again and helping them achieve autonomy and control over where and when they dialyze,” said Leslie Trigg, Chair and Chief Executive Officer. “As we look to the second half of the year, we see no change in underlying demand for Tablo. However, we have reflected in our guidance the staffing and inflationary pressures our provider customers are facing, as well as the work we need to do to regain commercial momentum following release of the Tablo ship hold.”

Second Quarter 2022 Financial Results

Revenue for the second quarter of 2022 was $25.1 million, compared to $25.2 million in the second quarter of 2021. Product revenue for the second quarter of 2022 was $19.6 million, representing a decrease of 4.9% compared to $20.6 million in the second quarter of 2021. Service and other revenue for the second quarter of 2022 was $5.4 million, representing an increase of 18.5% compared to $4.6 million in the second quarter of 2021.

Total gross profit for the second quarter of 2022 was $3.8 million, compared to $1.1 million for the second quarter of 2021. Total gross margin for the second quarter of 2022 was 15.1%, compared to 4.2% in the second quarter of 2021. On a non-GAAP basis, gross margin for the second quarter of 2022 improved to 15.9% from 4.4% in the second quarter of 2021. Product gross profit for the second quarter of 2022 was $1.9 million, compared to ($1.4) million of product gross loss in the second quarter of 2021. Product gross margin for the second quarter of 2022 was 9.7%, compared to (7.0)% in the second quarter of 2021. Service and other gross profit for the second quarter of 2022 was $1.9 million, compared to $2.5 million of service and other gross profit in the second quarter of 2021. Service and other gross margin for the second quarter of 2022 was 34.6%, compared to 54.5% in the second quarter of 2021.

Operating expenses for the second quarter of 2022 were $47.5 million, including research and development (R&D) expenses of $13.5 million, sales and marketing (S&M) expenses of $23.2 million, and general and administrative (G&A) expenses of $10.8 million. This compared to operating expenses of $31.0 million, including R&D expenses of $8.0 million, S&M expenses of $13.2 million, and G&A expenses of $9.7 million in the second quarter of 2021.

Excluding stock-based compensation expense, non-GAAP operating expenses for the second quarter of 2022 were $40.3 million, including R&D expenses of $11.7 million, S&M expenses of $20.3 million, and G&A expenses of $8.2 million.

Second quarter 2022 net loss was ($43.8) million, or ($0.92) per share, compared to net loss of ($30.2) million, or ($0.66) per share, for the same period in 2021. On a non-GAAP basis, net loss for the second quarter of 2022 was ($36.4) million, or ($0.77) per share, compared to non-GAAP net loss of ($26.3) million, or ($0.57) per share for the same period in 2021.

Total cash, including restricted cash, cash equivalents and short-term investments, was $295.4 million as of June 30, 2022.

Full Year 2022 Financial Guidance

Outset now projects revenue for 2022 of $105 million to $110 million, which represents 2% to 7% growth over 2021.

Webcast and Conference Call Details

Outset will host a conference call today, August 1, 2022, at 2:00 p.m. PT / 5:00 p.m. ET to provide a business update and discuss its second quarter 2022 financial results. The dial-in numbers are 877-451-6152 for domestic callers and 201-389-0879 for international callers. The conference ID is 13731999. A live webcast of the conference call will be available on the Investor Relations section of the Company's website at https://investors.outsetmedical.com. The webcast will be archived on the website following the completion of the call.

Use of Non-GAAP Financial Measures

The Company may report non‐GAAP results for gross profit/loss, gross margin, operating expenses, operating margins, net income/loss, basic and diluted net income/loss per share, other income/loss, and cash flows. These non-GAAP financial measures are in addition to, and not a substitute for, or superior to, financial measures calculated in accordance with GAAP. The Company’s financial measures under GAAP include stock-based compensation expense, as listed in the itemized reconciliations between GAAP and non‐GAAP financial measures included in this press release. Management has excluded the effects of this non-cash expense item in non‐GAAP measures to assist investors in analyzing and assessing past and future operating performance and period-to-period comparisons. There are limitations related to the use of non-GAAP financial measures because they are not prepared in accordance with GAAP, may exclude significant expenses required by GAAP to be recognized in the Company’s financial statements, and may not be comparable to non-GAAP financial measures used by other companies. The Company encourages investors to carefully consider its results under GAAP, as well as its supplemental non‐GAAP information and the reconciliation between these presentations, to more fully understand its business. Reconciliations between GAAP and non‐GAAP results are presented in the Appendix A of this press release.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements include, but are not limited to, statements about the Company’s possible or assumed future results of operations and financial position, including expectations regarding projected revenues (including sales into the home market and such sales as a percentage of revenues), gross margin, operating expenses, capital expenditures, profitability and outlook; statements regarding the Company’s overall business strategy, plans and objectives of management; the Company’s expectations regarding the market sizes and growth potential for Tablo and the total addressable market opportunities for Tablo; continued execution of the Company’s initiatives designed to reduce the cost of producing and shipping Tablo devices and its ability to achieve projected cost reductions at the level or within the timeframe estimated; the Company’s expectations with respect to anticipated benefits of the TPNIES approval, as well as the Company’s expectations regarding the impact of the COVID-19 pandemic and other macroeconomic factors on the Company as well as the impact on its customers and suppliers. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Factors that could cause actual results or other events to differ materially from those contemplated in this press release can be found in the Risk Factors section of Outset’s public filings with the Securities and Exchange Commission, including Outset’s latest annual and quarterly reports. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of their date and, except to the extent required by law, the Company undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise.

About Outset Medical, Inc.

Outset is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Tablo® Hemodialysis System, FDA cleared for use from the hospital to the home, represents a significant technological advancement that transforms the dialysis experience for patients and operationally simplifies it for providers. Tablo serves as a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere and by anyone. The integration of water purification and on-demand dialysate production enables Tablo to serve as a dialysis clinic on wheels, with 2-way wireless data transmission and a proprietary data analytics platform powering a new holistic approach to dialysis care. Tablo is a registered trademark of Outset Medical, Inc.

Outset Medical, Inc.
Condensed Statements of Operations
(in thousands, except per share amounts)
(unaudited)
		Three Months Ended										Six Months Ended
		June 30,										June 30,
		2022					2021					2022					2021
Revenue:
Product revenue		$	19,621				$	20,628				$	45,285				$	38,838
Service and other revenue			5,436					4,588					10,322					9,294
Total revenue			25,057					25,216					55,607					48,132
Cost of revenue:
Cost of product revenue (2)			17,718					22,077					40,828					42,654
Cost of service and other revenue			3,557					2,087					6,555					4,137
Total cost of revenue			21,275					24,164					47,383					46,791
Gross profit (1)			3,782					1,052					8,224					1,341
Gross margin (1)			15.1		%			4.2		%			14.8		%			2.8		%
Operating expenses:
Research and development (2)			13,521					8,032					24,352					15,602
Sales and marketing (2)			23,198					13,204					43,575					26,353
General and administrative (2)			10,784					9,722					20,493					18,968
Total operating expenses			47,503					30,958					88,420					60,923
Loss from operations			(43,721	)				(29,906	)				(80,196	)				(59,582	)
Other income (expense):
Interest income and other income, net			459					164					579					276
Interest expense			(481	)				(431	)				(903	)				(853	)
Loss before provision for income taxes			(43,743	)				(30,173	)				(80,520	)				(60,159	)
Provision for income taxes			96					35					211					74
Net loss		$	(43,839	)			$	(30,208	)			$	(80,731	)			$	(60,233	)
Net loss per share, basic and diluted		$	(0.92	)			$	(0.66	)			$	(1.69	)			$	(1.36	)
Shares used in computing net loss per share, basic and diluted			47,882					45,680					47,686					44,228

(1) Gross profit and gross margin by source consisted of the following:
		Three Months Ended										Six Months Ended
		June 30,										June 30,
		2022					2021					2022					2021
Gross profit
Product revenue		$	1,903				$	(1,449	)			$	4,457				$	(3,816	)
Service and other revenue			1,879					2,501					3,767					5,157
Total gross profit		$	3,782				$	1,052				$	8,224				$	1,341
Gross margin
Product revenue			9.7		%			(7.0	)	%			9.8		%			(9.8	)	%
Service and other revenue			34.6		%			54.5		%			36.5		%			55.5		%
Total gross margin			15.1		%			4.2		%			14.8		%			2.8		%
(2) Include stock-based compensation expense as follows:
		Three Months Ended										Six Months Ended
		June 30,										June 30,
		2022					2021					2022					2021
Cost of revenue		$	190				$	62				$	283				$	137
Research and development			1,808					643					2,966					1,808
Sales and marketing			2,864					1,052					4,570					2,794
General and administrative			2,552					2,180					4,601					5,050
Total stock-based compensation expense		$	7,414				$	3,937				$	12,420				$	9,789

Outset Medical, Inc.
Condensed Balance Sheets
(in thousands, except per share amounts)
		June 30,				December 31,
		2022				2021
		(Unaudited)
Assets
Current assets:
Cash and cash equivalents		$	75,497			$	182,348
Short-term investments			186,565				157,140
Accounts receivable, net			24,627				25,600
Inventories			53,689				39,185
Prepaid expenses and other current assets			5,399				5,529
Total current assets			345,777				409,802
Restricted cash			33,311				33,311
Property and equipment, net			15,245				12,964
Operating lease right-of-use assets			6,687				7,231
Other assets			216				156
Total assets		$	401,236			$	463,464
Liabilities and stockholders' equity
Current liabilities:
Accounts payable		$	2,753			$	1,763
Accrued compensation and related benefits			15,795				24,948
Accrued expenses and other current liabilities			23,261				13,789
Accrued warranty liability			3,444				3,704
Deferred revenue, current			7,752				6,340
Operating lease liabilities, current			1,235				1,151
Term loan, current			1,000				—
Total current liabilities			55,240				51,695
Accrued interest, noncurrent			960				721
Deferred revenue, noncurrent			205				312
Operating lease liabilities, noncurrent			6,261				6,893
Term loan, noncurrent			28,806				29,762
Total liabilities			91,472				89,383
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.001 par value; 5,000 shares authorized, and no shares issued and outstanding as of June 30, 2022 and December 31, 2021			—				—
Common stock, $0.001 par value; 300,000 shares authorized as of June 30, 2022 and December 31, 2021; 47,997 and 47,241 shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively			48				47
Additional paid-in capital			1,017,396				1,000,212
Accumulated other comprehensive loss			(955	)			(184	)
Accumulated deficit			(706,725	)			(625,994	)
Total stockholders' equity			309,764				374,081
Total liabilities and stockholders' equity		$	401,236			$	463,464

Outset Medical, Inc.
Condensed Statements of Cash Flows
(in thousands)
(unaudited)
		Six Months Ended June 30,
		2022				2021
Net cash used in operating activities		$	(76,910	)		$	(69,457	)
Net cash used in investing activities			(34,706	)			(104,267	)
Net cash provided by financing activities			4,765				153,026
Net decrease in cash, cash equivalents and restricted cash			(106,851	)			(20,698	)
Cash, cash equivalents and restricted cash at beginning of the period			215,659				328,283
Cash, cash equivalents and restricted cash at end of the period (1)		$	108,808			$	307,585
(1) The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the accompanying condensed balance sheets that sum to the total of the amounts shown in the accompanying condensed statements of cash flows (in thousands):
		June 30,
		2022				2021
Cash and cash equivalents		$	75,497			$	274,274
Restricted cash			33,311				33,311
Total cash, cash equivalents and restricted cash*		$	108,808			$	307,585
* The total cash, including restricted cash, cash equivalents and investment securities as of June 30, 2022 was $295.4 million; compared to $429.5 million as of June 30, 2021.

Appendix A
Outset Medical, Inc.
Results of Operations – Non-GAAP
(in thousands, except per share amounts)
(unaudited)
Reconciliation between GAAP and non-GAAP net loss per share:
		Three Months Ended										Six Months Ended
		June 30,										June 30,
		2022					2021					2022					2021
GAAP net loss per share, diluted		$	(0.92	)			$	(0.66	)			$	(1.69	)			$	(1.36	)
Stock-based compensation expense			0.15					0.09					0.26					0.22
Non-GAAP net loss per share, diluted		$	(0.77	)			$	(0.57	)			$	(1.43	)			$	(1.14	)
Reconciliation between GAAP and non-GAAP net loss:
		Three Months Ended										Six Months Ended
		June 30,										June 30,
		2022					2021					2022					2021
GAAP net loss, diluted		$	(43,839	)			$	(30,208	)			$	(80,731	)			$	(60,233	)
Stock-based compensation expense			7,414					3,937					12,420					9,789
Non-GAAP net loss, diluted		$	(36,425	)			$	(26,271	)			$	(68,311	)			$	(50,444	)
Reconciliation between GAAP and non-GAAP results of operations:
		Three Months Ended										Six Months Ended
		June 30,										June 30,
		2022					2021					2022					2021
GAAP gross profit		$	3,782				$	1,052				$	8,224				$	1,341
Stock-based compensation expense			190					62					283					137
Non-GAAP gross profit		$	3,972				$	1,114				$	8,507				$	1,478
GAAP gross margin			15.1		%			4.2		%			14.8		%			2.8		%
Stock-based compensation expense			0.8					0.2					0.5					0.3
Non-GAAP gross margin			15.9		%			4.4		%			15.3		%			3.1		%
GAAP research and development expense		$	13,521				$	8,032				$	24,352				$	15,602
Stock-based compensation expense			(1,808	)				(643	)				(2,966	)				(1,808	)
Non-GAAP research and development expense		$	11,713				$	7,389				$	21,386				$	13,794
GAAP sales and marketing expense		$	23,198				$	13,204				$	43,575				$	26,353
Stock-based compensation expense			(2,864	)				(1,052	)				(4,570	)				(2,794	)
Non-GAAP sales and marketing expense		$	20,334				$	12,152				$	39,005				$	23,559
GAAP general and administrative expense		$	10,784				$	9,722				$	20,493				$	18,968
Stock-based compensation expense			(2,552	)				(2,180	)				(4,601	)				(5,050	)
Non-GAAP general and administrative expense		$	8,232				$	7,542				$	15,892				$	13,918
GAAP total operating expense		$	47,503				$	30,958				$	88,420				$	60,923
Stock-based compensation expense			(7,224	)				(3,875	)				(12,137	)				(9,652	)
Non-GAAP total operating expense		$	40,279				$	27,083				$	76,283				$	51,271

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20220801005489/en/

Investor Contact

Jim Mazzola

Outset Medical

858-342-8272

jmazzola@outsetmedical.com

Lynn Lewis or Brian Johnston

Gilmartin Group

investors@outsetmedical.com

Media Contact

Nicole Shannon

Director, Marketing Communications for Outset Medical

nshannon@outsetmedical.com

Source: Outset Medical, Inc.

FAQ

What are the financial results for Outset Medical for Q2 2022?

Outset Medical reported Q2 2022 revenue of $25.1 million with a net loss of ($43.8) million.

What is Outset Medical's revenue guidance for the full year 2022?

Outset Medical projects revenue between $105 million and $110 million for 2022.

What improvements were made in Outset Medical's gross margin for Q2 2022?

The gross margin improved to 15.1% in Q2 2022, up from 4.2% in Q2 2021.

How much did Outset Medical's operating expenses increase in Q2 2022?

Operating expenses rose to $47.5 million in Q2 2022, compared to $31.0 million in Q2 2021.

Has Outset Medical resumed shipments of the Tablo® Hemodialysis System?

Yes, Outset Medical has resumed shipments of the Tablo® Hemodialysis System for home use following FDA clearance.